PF-07817883

DRUG5 trials

Sponsors

Pfizer

Conditions

COVID-19HealthySARS-CoV-2 Infection

Phase 1

A Study to Learn Safety and Blood Levels of PF-07817883 in Healthy People

CompletedNCT05580003

Start: 2022-10-17End: 2023-09-15Updated: 2024-11-21

A Study to Learn About How Itraconazole Affects the Blood Level of Study Medicine (PF-07817883) in Healthy Adults.

CompletedNCT05822440

Start: 2023-04-13End: 2023-07-10Updated: 2024-10-04

A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.

CompletedNCT05884554

Start: 2023-06-15End: 2024-06-27Updated: 2024-09-19

A Study to Learn How Renal Impairment Affects the Pharmacokinetics of PF-07817883.

CompletedNCT06586216

Start: 2024-09-10End: 2025-02-13Updated: 2025-02-19

Phase 2

A Study to Understand the Effect and Safety of the Study Medicine PF-07817883 in Adults Who Have Symptoms of COVID-19 But Are Not Hospitalized

CompletedNCT05799495

PfizerSARS-CoV-2 Infection

Start: 2023-05-23End: 2023-10-11Updated: 2024-10-09

Related Papers

Ibuzatrelvir potently reduced viral RNA levels despite a high rate of anti-S seropositivity: a post hoc analysis of serology of the phase 2b study

Scientific Reports2026-03-08

Virologic Response and Safety of Ibuzatrelvir, A Novel SARS-CoV-2 Antiviral, in Adults With COVID-19

Clinical Infectious Diseases2024-11-019 citations